3 Biotech Stocks to Buy and Hold for the Next 10 Years
The biotech industry can be risky and volatile, but there are advantages to investing in companies in this field. Many of them develop lifesaving drugs, the kinds we'll need until we can completely eradicate diseases, which doesn't seem likely to happen in the next decade.
Of course, investing in just any biotech stock won't do. It's important to decide whether a company has the innovative capabilities to stay relevant and continuously deliver strong returns. Let's consider three biotech stocks that have what it takes: CRISPR Therapeutics (NASDAQ: CRSP), Axsome Therapeutics (NASDAQ: AXSM), and Amgen (NASDAQ: AMGN).
CRISPR Therapeutics is on a roll. The company recently earned approval for its first product, Casgevy, a gene-editing therapy for a couple of rare blood diseases. Developed in collaboration with biotech giant Vertex Pharmaceuticals, Casgevy should have massive commercial success. CRISPR and Vertex estimate a total patient population of at least 35,000, and the treatment costs $2.2 million per patient in the U.S. Even grabbing just 30% of that target market would mean billions of dollars in revenue. There aren't many competitors to contend with, either, so things are looking good for CRISPR and Vertex.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
Die Aktie ist durchaus ein Favorit unsere Community mit 58 Buy-Einschätzungen und 2 Sell-Einschätzungen.
Ein leichtes Potenzial nach oben für Vertex Pharmaceuticals Inc. mit einem Kursziel von 450 € gegenüber dem aktuellen Kurs von 431.0 €.